CTOs on the Move


 
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase ...
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.furiex.com
  • 3900 Paramount Parkway Suite 150
    Morrisville, NC USA 27560
  • Phone: 919 456 7800

Executives

Name Title Contact Details

Similar Companies

Tock

Tock is a comprehensive platform built to fundamentally change the way restaurants think about and run their business. This includes a robust reservation, guest, and table management system for restaurants of all sizes across the globe.

Strategic Healthcare Programs

Strategic Healthcare Programs is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pancreatic Cancer Canada

Pancreatic Cancer Canada is a national foundation dedicated to improving pancreatic cancer survival rates through research, awareness, education, and advocacy in Canada.

Medwise Partners

Medwise Partners is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Questcor

We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our efforts are currently focused on the fields of neurology, nephrology and rheumatology, areas of medicine which have significant unmet medical needs. Our main product is H.P Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component. We are currently supporting research in a number of rare conditions, where there is significant unmet need for treatment alternatives to standard therapies. We are also actively supporting research efforts to better understand disease processes and therapeutic mechanisms of action in conditions where Acthar might potentially play a role in treatment.